Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer-Reference-Cited by-同舟云学术

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Published:2024-01-01 Issue:1 Volume:16 Page:209
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Damaskos Christos¹²^ORCID,Psilopatis Iason³^ORCID,Garmpi Anna⁴,Dimitroulis Dimitrios⁵,Nikolettos Konstantinos⁶,Vrettou Kleio⁷,Sarantis Panagiotis⁸^ORCID,Koustas Evangelos⁸,Kouraklis Gregory⁹,Antoniou Efstathios A.²¹⁰,Karamouzis Michail V.⁸^ORCID,Nikolettos Nikolaos⁶,Tsikouras Panagiotis⁶,Marinos Georgios¹¹,Kontomanolis Emmanouil⁶,Kontzoglou Konstantinos²⁵,Garmpis Nikolaos²¹⁰^ORCID

Affiliation:

1. Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece

2. N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

3. Department of Obstetrics and Gynecology, University Erlangen, Universitaetsstrasse 21–23, 91054 Erlangen, Germany

4. First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

5. Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

6. Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece

7. Department of Cytopathology, Sismanogleio General Hospital, 15126 Athens, Greece

8. Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

9. Department of Surgery, Evgenideio Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

10. Department of General Surgery and HPB Surgery of Adults and Children, Hygeia Hospital, 15123 Athens, Greece

11. Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, 11527 Athens, Greece

Abstract

Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. Materials and Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients. Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer. Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/16/1/209/pdf

Reference29 articles.

1. American Cancer Society (2022). Key Statistics for Breast Cancer: American Cancer Society, American Cancer Society.

2. Triple-negative breast cancer: A short review;Elias;Am. J. Clin. Oncol.,2010

3. Dass, S.A., Tan, K.L., Selva Rajan, R., Mokhtar, N.F., Mohd Adzmi, E.R., Wan Abdul Rahman, W.F., Tengku Din, T.A.D.A., and Balakrishnan, V. (2021). Triple negative breast cancer: A review of present and future diagnostic modalities. Medicina, 57.

4. American Cancer Society (2022). Triple Negative Breast Cancer: American Cancer Society, American Cancer Society.

5. Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., and Ma, X. (2022). Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol. Biomed., 3.